ALZHEIMER'S DISEASE

The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Lecanemab is the first drug to remove damage, but there are questions around its impact, side effects and use.

The cognitive disease affects communication skills and can have different causes, according to medical experts.

The Alzheimer’s Association San Antonio & South Texas Chapter had a successful year last year, and that was in part due to a fundraising effort for the group started as a sibling rivalry on social media.

The billionaire daughter of the Publix Super Markets founder has died after having early-onset Alzheimer's Disease, the company announced Wednesday. Carol Jenkins Barnett was 65. Barnett died Tuesday night at her home in Lakeland, Florida, Publix said in a news release.

Life expectancy has increased in recent decades, but researchers are looking for ways to further slow the aging process and extend human life, including warding off disease by targeting the biology of aging itself.

Donna Marino was arrested last Wednesday in Connecticut and charged with first-degree grand larceny and third-degree forgery.

Anderson Cooper reports on the 95-year-old crooner, Sunday for 60 Minutes.

Featuring splurge-worthy items to feed your design obsession Originally Appeared on Architectural Digest

Police arrested a man who they say is suspected of stabbing two Asian American women without warning Tuesday afternoon in San Francisco's Mid-Market area. A 54-year-old San Francisco man was arrested on suspicion of committing the attack several hours later, police told the station. Asian Americans have been the target of several unprovoked attacks in the San Francisco Bay Area in recent months.

SAN ANTONIO – Around the world, 50 million people are living with Alzheimer’s Disease and other dementias. Alzheimer’s is a degenerative brain disease and the most common form of dementia, and right now there is no cure. San Antonio organizations are working not only to fund research, but help local families weather the challenges. And it shook my world,” Nia Mostacero said. On top of the local research money raised from the walk the funds will help support caregivers information session support groups and the helpline.

The Walk To End Alzeimer’s will take place this Saturday, Oct. 10 and the woman organizing it knows all too well how difficult this disease is. My dad passed away from COVID on July 19 and my mom passed away Aug. 4,” Gibbons said. She doesn’t want the fight to end Alzeimer’s to end. “After seeing my parents go through it, we understand, so it’s all gonna be virtual,” Gibbons said. There will be a ceremony for the Walk To End Alzeimer’s and the walk will take place at 9:30 a.m.“They can walk wherever they want to, it doesn’t matter where they live, they can live out of state and still walk with us,” Gibbons said.

A new study found that repetitive negative thinking in later life was linked to cognitive decline and greater deposits of two harmful proteins responsible for Alzheimer's disease. Negative thinking behaviors such as rumination about the past and worry about the future were measured in over 350 people over the age of 55 over a two-year period. "Taken alongside other studies, which link depression and anxiety with dementia risk, we expect that chronic negative thinking patterns over a long period of time could increase the risk of dementia," Marchant said. The researchers suggest that mental training practices such as meditation might help promoting positive thinking while reducing negative thoughts, and they plan future studies to test their hypothesis. That's probably because optimists tend to have better health habits, said cardiologist Dr. Alan Rozanski, a professor of medicine at the Icahn School of Medicine at Mount Sinai, who studies optimism's health impacts.

The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March 21, 2019. Biogen shares rose Thursday after the biotech firm offered more data on its late-stage Alzheimer's drug, aducanumab. The data, presented at the Clinical Trials on Alzheimer's Disease conference, offered almost no new results from what the company previously released in October. Dr. Eric Siemers, an Alzheimer's expert who previously led Alzheimer's research at Eli Lilly, also noted the company offered a more detailed look but "almost the same as they showed" previously. Prior to the announcement, Biogen shares were halted at $286.83.

Biogen's stock could fall as much as 10% once it releases new data this week on its Alzheimer's drug, aducanumab, Baird biotech analyst Brian Skorney told CNBC on Monday. Shares of Biogen were down more than 2% in intraday trading Monday after Skorney wrote in a note to investors that he is skeptical Biogen's Alzheimer's drug will be approved by federal regulators. In March, Biogen pulled the plug on its Alzheimer's drug and sent its stock tanking after an analysis from an independent audit revealed the experimental medicine was unlikely to work. Biogen's drug targets a compound in the brain known as beta-amyloid, which is thought to play a role in the devastating disease by eroding synapses between nerve cells. Biogen is expected to release new data for its drug at the Clinical Trials on Alzheimer's Disease annual congress on Thursday.

CBS News medical contributor Dr. Holly Phillips discusses the symptoms of Alzheimer's, and the lesser known early-onset form of the disease.

A new study finds that being 'at a loss for words' might actually be a mysterious brain disorder called Primary Progressive Aphasia, often confused with Alzheimer's Disease. CBSN's Elaine Quijano has the details.

"Car Talk" host Tom Magliozzi Dies at 77 The popular radio host entertained listeners for 25 years on National Public Radio as one of the "Car Talk" guys. He died at 77 from complications of Alzheimer's Disease.

Alzheimer's disease disproportionately affects women The Alzheimer's Association finds one out of six women over the age of 65 could develop Alzheimer's. Only one out of 11 men will be diagnosed. Norah O'Donnell reports.